drugset / Trial / NCT00677105
A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.
Phase 1
Completed
92 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen Pharmaceutica N.V., Belgium · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of the drug (JNJ-24681585 a drug in development for cancer) in patients with advanced or refractory solid malignancies or lymphoma on the maximum dose that can be tolerated by these patients. The absorption, breakdown and elimination of the drug will be studied and in some patients, the effect of the food on these processes will also be examined.
Timeline
- Start
- 2007-08
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quisinostat | Small molecule | 2 mg | Oral |